Proinflammatory and Vasoactive Effects of Aβ in the Cerebrovasculature

Abstract: Aβ peptides are thought to be critical molecules in the pathophysiology of Alzheimer's disease (AD) and are the major protein constituents of senile plaques. In most AD cases, Aβ peptides also form some deposits in the cerebrovasculature, leading to cerebral amyloid angiopathy and hemorrhagic stroke. Regional cerebral hypoperfusion is one of the earlier clinical manifestations in both the sporadic and familial forms of AD. In addition, a variety of vascular risk factors of different etiologies (for instance, diabetes, hypertension, high cholesterol level, atherosclerosis, and smoking) constitute risk factors for AD as well, suggesting that functional vascular abnormalities may contribute to AD pathology. We studied the effect of Aβ on constrictor responses elicited by endothelin‐1 in isolated human cerebral arteries collected following rapid autopsies. We report that freshly solubilized Aβ potentiates endothelin‐1‐induced vasoconstriction in isolated human middle cerebral and basilar arteries. The vasoconstriction elicited by Aβ in these large human cerebral arteries appears to be completely antagonized by NS‐398, a selective cyclooxygenase‐2 inhibitor, or by SB202190, a specific p38 mitogen‐activated protein kinase inhibitor, suggesting that Aβ vasoactivity is mediated via the stimulation of a proinflammatory pathway. In addition, a similar proinflammatory response appears to be mediated by Aβ in isolated human brain microvessels, resulting in an increased production of prostaglandin E2 and F2α. Using a scanner laser Doppler imager, we show a progressive decline with aging in cortical perfusion level in transgenic APPsw mice (line 2576) compared with age‐matched control littermates. The relation between the acute proinflammatory and vasoactive properties of Aβ and the chronic progressive hypoperfusion seen in AD (and transgenic models thereof) is yet to be elucidated.

[1]  C. Iadecola,et al.  Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. , 2002, American journal of physiology. Heart and circulatory physiology.

[2]  R. Kalaria,et al.  Increased collagen content of cerebral microvessels in Alzheimer's disease , 1995, Brain Research.

[3]  D. Premkumar,et al.  Molecular aspects of inflammatory and immune responses in Alzheimer's disease , 1996, Neurobiology of Aging.

[4]  F. Crawford,et al.  Role of Peroxynitrite in the Vasoactive and Cytotoxic Effects of Alzheimer's β-Amyloid1–40Peptide , 1998, Experimental Neurology.

[5]  A. Guerguerian,et al.  Key role for cyclooxygenase-2 in PGE2 and PGF2α receptor regulation and cerebral blood f low of the newborn. , 1997, American journal of physiology. Regulatory, integrative and comparative physiology.

[6]  T. Montine,et al.  Elevated CSF prostaglandin E2 levels in patients with probable AD. , 1999, Neurology.

[7]  M. Mullan,et al.  β-Amyloid-mediated vasoactivity and vascular endothelial damage , 1996, Nature.

[8]  R. Roos,et al.  Dementia in hereditary cerebral hemorrhage with amyloidosis‐Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles , 2001, Annals of neurology.

[9]  George A. Carlson,et al.  Exogenous Aβ1–40 Reproduces Cerebrovascular Alterations Resulting from Amyloid Precursor Protein Overexpression in Mice , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  J. C. Torre Impaired Cerebromicrovascular Perfusion: Summary of Evidence in Support of Its Causality in Alzheimer's Disease , 2000 .

[11]  H. Wiśniewski,et al.  Migration of perivascular cells into the neuropil and their involvement in β-amyloid plaque formation , 2004, Acta Neuropathologica.

[12]  P. R. Hof,et al.  Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders , 1994, Acta Neuropathologica.

[13]  Fiona Crawford,et al.  Soluble Alzheimers β-amyloid constricts the cerebral vasculature in vivo , 1998, Neuroscience Letters.

[14]  O. Bugiani,et al.  Thickening of the basement membrane of cortical capillaries in Alzheimer's disease , 2004, Acta Neuropathologica.

[15]  C. Soto,et al.  Alzheimer's β‐amyloid vasoactivity: identification of a novel β‐amyloid conformational intermediate , 1998 .

[16]  D. Cornfield,et al.  Aβ-peptides enhance vasoconstriction in cerebral circulation , 2001 .

[17]  L. Thal,et al.  Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease , 1996, Neurology.

[18]  C. Iadecola,et al.  Increased Susceptibility to Ischemic Brain Damage in Transgenic Mice Overexpressing the Amyloid Precursor Protein , 1997, The Journal of Neuroscience.

[19]  A. Fendrick Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy. , 2002, Cleveland Clinic journal of medicine.

[20]  C. Lemere,et al.  Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. , 2001, The American journal of pathology.

[21]  D. Borchelt,et al.  SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein , 1999, Nature Neuroscience.

[22]  M. Shigeta,et al.  A Follow-Up Study of the Family with the Swedish APP 670/671 Alzheimer’s Disease Mutation , 1999, Dementia and Geriatric Cognitive Disorders.

[23]  J. Price,et al.  Beta-amyloid-induced coronary artery vasoactivity and endothelial damage. , 1997, Journal of cardiovascular pharmacology.

[24]  C. Iadecola,et al.  Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Selkoe,et al.  Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease , 1989, Journal of Neuroimmunology.

[26]  L. Lue,et al.  Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. , 1996, Journal of neuropathology and experimental neurology.

[27]  R. Mrak,et al.  Interleukin‐1 Expression in Different Plaque Types in Alzheimer's Disease: Significance in Plaque Evalution , 1995, Journal of neuropathology and experimental neurology.

[28]  V. Fischer,et al.  Altered angioarchitecture in selected areas of brains with Alzheimer's disease , 2004, Acta Neuropathologica.

[29]  P. Amenta,et al.  The basement membrane in pathology. , 1983, Laboratory investigation; a journal of technical methods and pathology.

[30]  Mark A. Smith,et al.  Cerebrovascular muscle atrophy is a feature of Alzheimer's disease , 1998, Brain Research.

[31]  E. Ellis,et al.  Isoprostanes: free radical-generated prostaglandins with constrictor effects on cerebral arterioles. , 1997, Stroke.

[32]  A. Placzek,et al.  Aβ Vasoactivity in Vivo , 2000 .

[33]  D. Borchelt,et al.  Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer’s Disease neuropathology , 2002, Neurobiology of Aging.

[34]  P. Hof,et al.  Brain Microvascular Changes in Alzheimer's Disease and Other Dementias a , 1997, Annals of the New York Academy of Sciences.

[35]  J. C. Torre,et al.  Alzheimer Disease as a Vascular Disorder: Nosological Evidence , 2002 .

[36]  K. Ashe,et al.  Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.

[37]  J. Wegiel,et al.  Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease , 2004, Acta Neuropathologica.

[38]  W F Stewart,et al.  Risk of Alzheimer's disease and duration of NSAID use , 1997, Neurology.

[39]  W. Grizzle,et al.  Dissociation of Cyclic Inositol Phosphohydrolase Activity from Annexin III (*) , 1996, The Journal of Biological Chemistry.

[40]  M. Mullan,et al.  Characteristics of thein VitroVasoactivity of β-Amyloid Peptides , 1998, Experimental Neurology.

[41]  Tetsuo Hashimura,et al.  Morphological Changes of Blood Vessels in the Brain with Alzheimer's Disease , 1988 .

[42]  George A. Carlson,et al.  Alterations in Cerebral Blood Flow and Glucose Utilization in Mice Overexpressing the Amyloid Precursor Protein , 2002, Neurobiology of Disease.

[43]  R. Veerhuis,et al.  Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain , 2000, Acta Neuropathologica.

[44]  G. Hellermann,et al.  Physiological levels of β-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production , 2001 .

[45]  P. Weigel,et al.  Microvessels from Alzheimer's disease brains kill neurons in vitro. , 1999, The American journal of pathology.

[46]  W. Wendling,et al.  Effects of prostaglandin F2 alpha and thromboxane A2 analogue on bovine cerebral arterial tone and calcium fluxes. , 1991, Stroke.

[47]  D. Selkoe,et al.  Amyloid β-Protein and the Genetics of Alzheimer's Disease* , 1996, The Journal of Biological Chemistry.

[48]  T. Town,et al.  Soluble β-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway , 2000, Neurobiology of Aging.

[49]  T. Town,et al.  Aβ Vasoactivity: An Inflammatory Reaction , 2000 .

[50]  J. van Ryn,et al.  Clinical experience with cyclooxygenase-2 inhibitors , 1999, Inflammation Research.

[51]  P. Weigel,et al.  Cerebrovasculature‐mediated Neuronal Cell Death , 2000, Annals of the New York Academy of Sciences.

[52]  P. Mcgeer,et al.  Inflammation of the brain in Alzheimer's disease: implications for therapy , 1999, Journal of leukocyte biology.

[53]  R. Kalaria The role of cerebral ischemia in Alzheimer’s disease , 2000, Neurobiology of Aging.

[54]  L. Lue,et al.  Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .

[55]  P. Grammas A damaged microcirculation contributes to neuronal cell death in Alzheimer’s disease☆ , 2000, Neurobiology of Aging.

[56]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[57]  C. Masters,et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.

[58]  T. Miyakawa,et al.  Observations of Microvessels in the Brain with Alzheimer's Disease by the Scanning Electron Microscopy , 1991, The Japanese journal of psychiatry and neurology.

[59]  P. Hedera,et al.  Differential degeneration of the cerebral microvasculature in Alzheimer's disease. , 1995, Neuroreport.

[60]  Luz Claudio,et al.  Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients , 1995, Acta Neuropathologica.

[61]  P. Aisen,et al.  Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain , 1998, Neuroscience.

[62]  P. Grammas,et al.  Inflammatory factors are elevated in brain microvessels in Alzheimer’s disease , 2001, Neurobiology of Aging.

[63]  D. Paris,et al.  Pro-inflammatory effect of freshly solubilized β-amyloid peptides in the brain , 2002 .

[64]  J. Overmier,et al.  Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice , 2001, Neurobiology of Aging.

[65]  Douglas Walker,et al.  Inflammation and Alzheimer's disease pathogenesis , 1996, Neurobiology of Aging.

[66]  P. Aisen,et al.  Regional distribution of cyclooxygenase‐2 in the hippocampal formation in Alzheimer's disease , 1999, Journal of neuroscience research.